Booster shot for Moms-to-Be could shield newborns from deadly infections

NCT ID NCT06592586

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows women who previously received the GBS-NN/NN2 vaccine during pregnancy to see how long their immune protection lasts. It also tests whether a booster dose given in a new pregnancy is safe and boosts immunity, aiming to protect newborns from group B strep infections like sepsis, pneumonia, and meningitis. About 338 women in Denmark and South Africa are taking part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GBS-NN/NN2 vaccine
What this could lead to
If successful, this could show that a booster dose of the GBS vaccine during a later pregnancy maintains protection for newborns against life-threatening group B strep infections.
What could go wrong
This is a follow-up study with a small number of participants (338) and results may not apply to all populations. The vaccine is still in Phase 2/3, so it is not yet proven to be effective or safe for widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BACTERIAL INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Aarhus Universitetshospital

    Aarhus N, Central Jutland, 8200, Denmark

  • Hvidovre Hospital - Department Of Obstetrics And Gynaecology

    Copenhagen, Capital Region, 2650, Denmark

  • Sefako Makgatho Health Sciences University, Medunsa Clinical Research Unit (MeCRU)

    Ga-Rankuwa, Gauteng, 0204, South Africa

  • Setshaba Research Centre

    Pretoria, Guateng Province, 0152, South Africa

  • Sygehus Lillebælt - Kolding Sygehus

    Kolding, Region Syddanmark, 6000, Denmark

  • Wits Reproductive Health and HIV Institute (Wits RHI)

    Johannesburg, Guateng Province, 2001, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.